Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 35 to 65

Effects of Mirabegron on Beige Fat Activation in Prediabetic Patients

Official title: Mechanisms for Activation of Beige Adipose Tissue in Humans

Run by University of Kentucky · NCT04666636 · Data updated 2026-11-12

This study is testing if the drug mirabegron can help people with prediabetes by activating a type of fat that may improve their blood sugar levels and overall metabolism.

More Prediabetes trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages35 Years to 65 Years
SexAll
Enrollment65 (estimated)
SponsorUniversity of Kentucky
Academic / other
Locations1 site (Lexington, Kentucky)
StatusRecruiting
StartedDecember 7, 2020
Main results expectedJune 2027
Study endsDecember 2027
Registry record updatedJuly 7, 2026
Trial IDNCT04666636 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults with a BMI between 27 and 45 who have been diagnosed with prediabetes.

Probably not a fit

Patients with diabetes or those on chronic anti-diabetic medications are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the impact of the drug mirabegron, a specific ß3 adrenergic receptor agonist, on glucose tolerance and adipose tissue in individuals with prediabetes. The study aims to explore how mirabegron can activate beige adipose tissue, which may help improve insulin sensitivity and glucose homeostasis. Participants will be randomly assigned to receive either mirabegron or a placebo, and their metabolic responses will be monitored throughout the trial. The research is based on the premise that activating beige fat could provide a novel approach to managing prediabetes and obesity.

Why it matters

Potential benefit: If successful, this study could lead to new treatment options for improving glucose metabolism and preventing the progression of prediabetes.

How similar studies have gone: Previous studies have shown promising results with similar approaches using ß3 adrenergic receptor agonists in obese populations, indicating potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* BMI 27-45
* prediabetes (A1c 5.7-6.4)
* impaired fasting glucose or impaired glucose tolerance

Exclusion Criteria:

* diabetes
* chronic use of anti-diabetic medication
* acute or chronic inflammatory condition
* unstable medical condition
* cancer
* renal insufficiency
* any contraindication for Mirabegron
* BMI \>45

Where it's running

  • University of Kentucky
    Lexington, Kentucky, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.